Different approaches for treating melanoma with Gp-100 as an antigen have been developed, including Gp-100-based vaccines, mRNA electroporation of dendritic cells, and fusion proteins named IMCGp-100 or tebentafusp. This evidence concerns the gene PMEL and melanoma.